These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10088614)

  • 21. Global role of the immune system in identifying cancer initiation and limiting disease progression.
    Disis ML; Lyerly HK
    J Clin Oncol; 2005 Dec; 23(35):8923-5. PubMed ID: 16339754
    [No Abstract]   [Full Text] [Related]  

  • 22. The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome.
    Redfern AD; Spalding LJ; Thompson EW
    Clin Exp Metastasis; 2018 Apr; 35(4):285-308. PubMed ID: 29948647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment.
    Roussos ET; Keckesova Z; Haley JD; Epstein DM; Weinberg RA; Condeelis JS
    Cancer Res; 2010 Oct; 70(19):7360-4. PubMed ID: 20823151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism.
    Trujillo-Santos J; Bergmann JF; Bortoluzzi C; López-Reyes R; Giorgi-Pierfranceschi M; López-Sáez JB; Ferrazzi P; Bascuñana J; Suriñach JM; Monreal M
    J Thromb Haemost; 2017 Mar; 15(3):429-438. PubMed ID: 28120516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A validation of the parametric assessment of the time of clonogen progression by simulation modelling].
    Ivankov AA; Tsodikov AD; Iakovlev AIu
    Vopr Onkol; 1993; 39(4-6):220-5. PubMed ID: 7975401
    [No Abstract]   [Full Text] [Related]  

  • 27. Why RECIST works and why it should stay--reply to counterpoint.
    Sharma MR; Maitland ML; Ratain MJ
    Cancer Res; 2012 Oct; 72(20):5158. PubMed ID: 22952220
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
    Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
    Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The treatment of patients with low tumour burden and/or slow growing disease.
    Maughan TS
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S67-75. PubMed ID: 21944032
    [No Abstract]   [Full Text] [Related]  

  • 30. Once daily versus twice daily enoxaparin for acute pulmonary embolism in cancer patients.
    King AC; Ma MQ; Chisholm G; Toale KM
    J Oncol Pharm Pract; 2016 Apr; 22(2):265-70. PubMed ID: 25888639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A glass of Champagne!].
    Hügli A
    Rev Med Suisse; 2015 May; 11(474):1091. PubMed ID: 26118236
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
    Calmy A; Vallier N; Nguyen A; Lange JM; Battegay M; de Wolf F; Reiss P; Lima VD; Hirschel B; Hogg RS; Yip B; Montaner JS; Wit FW; ; ;
    Antivir Ther; 2009; 14(7):931-8. PubMed ID: 19918097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth factor signalling pathways in cancer progression: complexities and therapeutic opportunities. Proceedings of the 2nd Tenovus/AstraZeneca Workshop. April 20-21, 2006. Cardiff, United Kingdom.
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S1-135. PubMed ID: 17259551
    [No Abstract]   [Full Text] [Related]  

  • 34. Always Look On the Bright Side: Anti-Tumor Functions of Neutrophils.
    Vols S; Sionov RV; Granot Z
    Curr Pharm Des; 2017; 23(32):4862-4892. PubMed ID: 28677504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Redefining cancer and cure.
    Hutchinson L
    Nat Rev Clin Oncol; 2016 Apr; 13(4):199. PubMed ID: 26997459
    [No Abstract]   [Full Text] [Related]  

  • 36. [AMPK in the cancer research field: tumor progression by ARK5].
    Suzuki A; Esumi H
    Seikagaku; 2006 May; 78(5):392-403. PubMed ID: 16780110
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.
    Herin H; Aspeslagh S; Castanon E; Dyevre V; Marabelle A; Varga A; Postel Vinay S; Michot JM; Ribrag V; Gazzah A; Bahleda R; Mir O; Massard C; Hollebecque A; Soria JC; Baldini C
    Eur J Cancer; 2018 May; 95():68-74. PubMed ID: 29635146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
    Wilson MK; Karakasis K; Oza AM
    Lancet Oncol; 2015 Jan; 16(1):e32-42. PubMed ID: 25638553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overcoming the tumor microenvironment: the role of nanohyperthermia.
    Silva AK; Nicolas-Boluda A; Fouassier L; Gazeau F
    Nanomedicine (Lond); 2017 Jun; 12(11):1213-1215. PubMed ID: 28520515
    [No Abstract]   [Full Text] [Related]  

  • 40. Dodging a dogma: is treating beyond progression beneficial?
    Naing A; Kurzrock R
    Cancer Chemother Pharmacol; 2013 May; 71(5):1385-6. PubMed ID: 23443308
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.